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ABSTRACT: Product development refers to the transformation process of an idea into a product or service. It can be 
applied to any sector, but special attention must be given to each industry particularities. In the case of medical devices, 
the development process should consider the multiple definitions of the term ‘medical device’, a vast regulatory 
framework as well as numerous organizations that evaluate the devices’ safety and effectiveness before entering the 
market. It should also consider various stakeholders and a variety of requirements regarding risk and quality. Currently, 
literature regarding product development methodologies applied to medical devices is scarce, and there is no graphical 
representation of the process addressing the environment in which it occurs. Here such representation, for the European 
market, is made in order to help to understand how medical devices are developed, evaluated and approved. The 
development process of medical devices was depicted because it is the most practical, easiest and fastest way to 
maintain, understand and communicate information. Furthermore, it facilitates the identification of the elements driving 
the process and reduces the complexity of the reality being represented. As the diagram presented is generic, it can be 
applied to every segment of the medical device industry. In addition, it can be both used by designers and management 
to guide the process, implement quality standards, support decision and select tools. 
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1 INTRODUCTION  
Product development refers to the transformation process 
of ideas into commercial products [1]. Typically, it starts 
with the recognition of a need. Then, the problems that 
customers aim to solve by buying new products are 
identified (customer needs). Following, numberless ideas 
to satisfy the needs are generated but usually only one is 
developed and optimized. Prototypes or pre-series are 
produced and evaluated by a restricted number of clients 
and, if they perform well, the process ends with the 
launch into the market. 
In spite of the differences among product development 
processes, it is possible to define a generic procedure 
since they share common tasks and features. The 
application of such a procedure has many advantages 
such as facilitate planning, increase predictability, help 
to improve quality, reduce costs, and compress cycle 
times [2-4]. However, is possible to obtain further 
benefits if a dedicated procedure is used, that is, a 
procedure that considers the characteristics of the 
product being developed and the environment in which 
the development occurs. 
This paper presents the differentiating characteristics of 
medical devices and suggests a dedicated product 
development methodology. The procedure is presented 
graphically because that is the most practical, easiest and 
fastest way to maintain, understand and communicate 
information. Furthermore, it facilitates the identification 
of the elements driving the process and reduces the 
complexity of the reality being represented. This 
representation, besides helping to understand how 
medical devices are developed, evaluated and approved, 
will guide both managers and designers during the 
development process. It will also support decision 
making, the selection of tools and the implementation of 
quality standards. 
This article is organized as follows. After the 
presentation of the particular characteristics of medical 
devices, a review regarding medical devices 
development methodologies is made. Following, the new 
representation for the development process of medical 
devices is described. Finally, conclusions are drawn, and 
possible future perspectives are indicated. 
 
  
2 CHARACTERISTICS OF MEDICAL 
DEVICES 
Medical devices encompass distinct apparatuses ranging 
from dental floss to lab-on-a-chip technology and are 
used in different settings, such as our homes and 
hospitals. They also have several users, i.e., clients, who 
use the devices differently and with dissimilar 
expectations [5]. 
Despite the fact that different definitions for the term 
‘medical device’ coexist, overall, it refers to any 
apparatus, software or material intended to be used in the 
diagnosis, prevention, monitoring, treatment or 
alleviation of a disease or an injury [6]. The differences 
in the definition reflect the regulatory system with which 
the devices must comply, which in turn affect the 
industry performance. 
It is possible to classify medical devices according to 
several criteria. While some categorizations have no 
impact on the device, others, like the risk classification, 
determine the legislation the device must comply with 
and its path to market. 
Medical devices interact with human fluids and tissue 
and as such cannot be disposed like other products. This 
is one of the reasons for considering carefully the entire 
lifecycle of the devices during the product development. 
To ensure the safety of both patients and healthcare 
providers, medical devices are highly regulated. During 
their development regulations, standards and guidelines 
regarding safety, quality, effectiveness, materials and 
others requirements must be considered. Besides these 
documents, there are entities responsible to evaluate if 
the devices conform. After the device enters the market, 
monitoring continues to evaluate the risk the device 
actually poses and to record adverse events; analyses are 
conducted to determine coverage and reimbursement 
policies. 
 
3 DEVELOPMENT OF MEDICAL 
DEVICES 
The development of medical devices is both capital and 
technologically intensive requiring highly qualified 
personnel with different backgrounds ranging from 
medical doctors to engineers. It is often the case that 
design requirements are incomplete and complex, and 
result from ambiguous situations. Furthermore, the 
devices’ lifecycle is similar to or even longer than the 
development cycle, and research happens in every 
direction. These reasons can explain why most 
commonly the development of novel devices is 
incremental with each model slightly different from its 
previous generation [7]. In this section, some of the 
research regarding methodologies for the development of 
medical devices is presented. 
As the development of medical devices is complex, it is 
common for regulatory bodies to offer consultancy 
services to help manufacturers deal with regulations and 
standards. For example, the British National Health 
Service (NHS) of the National Innovation Centre (NIC) 
has available online free-to-use tools to support the 
development of innovations [8]. Using the ‘Scorecard’ it 
is possible to rank ideas and, by browsing through 
‘Navigator’, one can structure the development of a 
novel device. 
In 1997, the FDA (Food and Drug Administration) 
presented in the document “Design Control Guidance for 
Medical Device Manufacturers” the waterfall model as a 
tool for introducing new product design controls. Some 
years later, the same institution encouraged 
manufacturers to shift to the total product life cycle 
(TPLC) model, a holistic approach to managing products 
through their lifecycle and making improvements to new 
products based on experiences with current products [9]. 
In their work, Aitchison et al. [10] described the design 
process for implantable orthopedic medical devices. The 
process was represented sequentially with 7 stages 
separated by design reviews to evaluate design 
requirements, assess the capability of the design and 
identify problems. 
Aguwa et al. [11] proposed an integrated fuzzy-based 
modular architecture for medical device design and 
development. In their work, the development of medical 
devices involves 4 steps. The first step refers to the 
functional and physical decomposition analyses of a 
medical device or system. The second step includes the 
selection of the performance parameters and the 
identification of the key metrics. Then, there is the 
evaluation of candidate modules. This is a phase that 
consists of two tasks: the development of a formal, 
structured process for engineering judgment of candidate 
modules with respect to the selected design objective 
metrics, and the development of a fuzzy logic model for 
transforming the subjective judgments into a set of 
performance indices. The fourth and final stage is 
product modularization using a multi-optimization 
model. 
A stage-gate process is proposed by Pietzsch et al. [12]. 
The process includes the following 6 phases: 
predevelopment activities; opportunity and risk analysis; 
concept and feasibility; design, development, 
verification and validation; product launch preparation; 
and product launch and post launch assessment. 
Das et al. [13] propose an attribute-driven concurrent 
engineering (ADCE) process for the development of 
medical devices. 
Medical devices are a regulated product and, as such, 
have to comply with multiple standards, regulations and 
also guidelines regarding varied topics like safety, 
quality, risk management and others. To overcome this 
fact, Alexander et al. [14] recommend, along with a 
concurrent engineering approach, the application of 
design for X methods. Medina et al. [15] go further 
suggesting guidelines to design for FDA (DfFDA) that 
should be used, when appropriate, with another design 
for X methods such as design for assembly (DfA), 
design for manufacturing (DfM), design for reliability 
(DfR), design for quality (DfQ), design for validation 
(DfV) and design for usability (DfU). Design for FDA 
  
aims to increase awareness about regulatory compliance 
and promote designers to consider the regulations 
throughout the development process of medical devices. 
Literature shows that there is a concern in addressing the 
medical device specificities. However, each author 
focuses in a single aspect. In the following section, it is 
suggested an integrated methodology for the 
development of medical devices. 
 
4 PROPOSED MODEL 
Regardless its complexity, every medical device must 
comply with similar requirements regarding quality, 
safety and effectiveness. The model proposed here is 
generic and, as long as it is custom-tailored, it can 
accommodate the specificities of any device. This model 
aims to describe the European environment in which 
medical devices are developed, i.e., indicate the 
development process’ inputs and outputs. 
The representation of the development process of 
medical devices was accomplished in two phases. 
During the first phase, information was gathered from 
literature on product development methodologies and 
medical devices, and the process was implemented using 
Business Process Model and Notation (BPMN) [16]. 
During the second phase, the first version of the 
graphical representation was discussed; several 
structured interviews were conducted, and an online 
survey (based on the work of Medina et al. [17]) was 
created and made available among members of 
academia, industry and regulatory bodies. With the 
feedback obtained, the model was completed. 
As Figure 1 shows, the development of a medical device 
can be described as a cycle composed of the following 
phases: idea creation, concept development, design, 
regulatory approval and clearance, and post-market 
surveillance and vigilance. The process is highly 
iterative and the borders of the phases are blurred. In 
Europe, in order to start the regulatory approval and 
clearance stage, one has to have the medical device and 
its manufacturing process completely defined because 
both the quality of the product and production are 
assessed. 
 
Figure 1: Medical device development process. 
Idea creation can be decomposed into several tasks 
(Figure 2). It can start in various ways ranging from the 
identification of a clinical need to the identification of a 
capability, i.e., new knowledge or technology. In order 
to proceed, not only does the commercial potential of the 
market opportunity have to be assessed, but also its 
readiness or, in other words, whether there is suitable 
technology, the manufacturing process is feasible or the 
market is prepared. If the opportunity has potential, the 
development of the medical device has to be planned and 
a decision regarding the markets in which the device will 
be commercialized has to be made. This decision will 
dictate the regulatory framework; here, it is addressed 
the European one. 
The next phase, concept development (Figure 3), is an 
iterative process that starts with the analysis of 
competitive products and the voice of the customer, i.e., 
the process of capturing the customers’ expectations, 
preferences and aversions (Figure 4). The latter is a sub-
process that starts with the identification of the customer; 
in this context, ‘customer’ represents those that are 
involved in the development of the medical device, from 
the maker to the user. During this stage, the management 
of intellectual property (Figure 5) must be considered 
constantly to protect new ideas/inventions and not to 
infringe on existing patents or utility models. 
During the design phase (Figure 6), both product (Figure 
7) and manufacture (Figure 8) design can be performed 
either sequentially or concurrently. The management of 
intellectual property is once again a constant, and the 
hazard analysis (Figure 9) should be conducted 
frequently to minimize risks and also to prepare post-
market surveillance. 
The approval process differs from country to country; 
Figure 10 shows the European process. 
Post-market activities are divided into two categories: 
post-market surveillance (PMS) and vigilance. The first 
is a proactive measure that consists in the collection of 
data regarding the quality, safety and performance of 
medical devices once they have entered the market. 
Vigilance, on the other hand, is a reactive measure that 
consists in the report of incidents that may occur when 
medical devices do not perform as intended, leading to 
injury or, in the worst case, to death. With vigilance, one 
aims to protect the health and safety of both patients and 
healthcare professionals, evaluate incidents and avoid 
relapses, and learn from experience. 
Post-market activities, besides being a regulatory 
obligation, are a good business practice because they 
help manufacturers to understand the performance of 
medical devices once they enter the market. 
Furthermore, they provide feedback that is essential to 
maintain quality and consumer satisfaction and allow the 
promptly deployment of warning and product recall 
procedures in case of incidents. 
The requirements for PMS can be found in the European 
Unions' Medical Device Directives, the quality standards 
ISO 9001 and ISO 13485, and the risk management 
standard ISO 14971. This information can be 
  
complemented by two guidelines published by the 
European Commission: MEDDEV 2.12-1 rev 6 from 
December 2009 and NB-MED/2.12/Rec1. 
The responsibility over post-market surveillance lies 
over manufacturers as well as competent authorities, 
custom officials, notified bodies, authorized 
representatives, importers/distributers and users. 
 
 
Figure 2: Idea creation process. 
 
 
Figure 3: Concept development process. 
 
  
 
Figure 4: Voice of the customer process. 
 
 
Figure 5: Management of the intellectual process. 
 
  
 
Figure 6: Design process. 
 
 
Figure 7: Product design. 
 
 
Figure 8: Manufacture design. 
 
 
Figure 9: Hazard analysis process. 
 
  
 
Figure 10: Flowchart with the European path to market. 
 
5 CONCLUSIONS 
In spite of the graphic representation of the product 
development process not being new, so far, there is not a 
representation specific to medical devices. These 
products justify such a representation because they have 
features that make them peculiar. In this paper, those 
features were presented together with a representation of 
the European environment in which medical devices are 
developed. In the future, it is relevant to repeat this 
exercise to the American market since it is the world's 
largest. 
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